Summary
Danaher Corporation's 2017 10-K filing reveals a year of robust sales growth driven by its Life Sciences and Diagnostics segments, which together represented over 60% of total revenue. The company's strategic focus on portfolio enhancement through acquisitions, operational improvements via the Danaher Business System (DBS), and talent management continues to be a core driver of its performance. Despite a challenging macroeconomic environment and increased competition in some markets, Danaher demonstrated resilience with core sales growth, indicating underlying strength in its diverse business units. The company's commitment to innovation and customer-centricity is evident in its continued investment in research and development across all segments. Financially, Danaher reported strong sales growth, supported by strategic acquisitions and organic growth initiatives. The company managed its debt effectively, with a focus on maintaining a healthy balance sheet. Investors should note the impact of the Tax Cuts and Jobs Act of 2017, which introduced significant changes to the U.S. tax landscape, including a one-time Transition Tax. Danaher provided a provisional estimate for its impact, aiming for a future effective tax rate between 20-21%. The company's diversified business model, global reach, and consistent application of DBS provide a solid foundation for continued value creation.
Financial Highlights
53 data points| Revenue | $15.52B |
| Cost of Revenue | $6.95B |
| Gross Profit | $8.57B |
| R&D Expenses | $956.40M |
| SG&A Expenses | $5.04B |
| Operating Income | $2.57B |
| Interest Expense | $140.10M |
| Net Income | $2.49B |
| EPS (Basic) | $3.58 |
| EPS (Diluted) | $3.53 |
| Shares Outstanding (Basic) | 695.80M |
| Shares Outstanding (Diluted) | 706.10M |
Key Highlights
- 1Consolidated sales increased by 8.5% to $18.3 billion in 2017, driven by strong performance in Life Sciences and Diagnostics segments.
- 2Core sales, excluding acquisitions and currency impacts, grew by 3.5%, showcasing underlying business momentum.
- 3Life Sciences segment revenue grew 6.5% to $5.7 billion, with core sales up 4.0%, led by mass spectrometry and filtration technologies.
- 4Diagnostics segment revenue increased significantly by 16.0% to $5.8 billion, with core sales up 4.0%, bolstered by the acquisition of Cepheid.
- 5The company reported a substantial increase in R&D expenditures to $1.13 billion, highlighting a commitment to innovation.
- 6Danaher successfully managed its debt, with total debt decreasing to $10.5 billion from $12.3 billion in the prior year.
- 7The company provided a provisional estimate for the Tax Cuts and Jobs Act impact, anticipating an effective tax rate of 20-21% for 2018.